Paclitaxel (PTX) is a first-line drug for late-stage non-small cell lung cancer (NSCLC)
patients who do not benefit from targeted therapy or immunotherapy. However, patients …

Purpose Paclitaxel is used as the first-line chemotherapy for Non-Small Cell Lung Cancer
(NSCLC), but acquired resistance becomes a critical problem. Several mechanisms have …

It has been approximately ten years since the Food and Drug Administration (FDA)
approved paclitaxel for the treatment of platinum resistant epithelial ovarian carcinoma …

Paclitaxel (PTX) is a microtubule-targeting drug widely used for the treatment of a variety of
cancers. However, drug resistance can emerge after a series of treatments, and this can …

Paclitaxel (PTX) is a chemotherapeutic agent that is used to treat a variety of cancers,
including non-small cell lung cancer (NSCLC). However, the emergence of drug resistance …

Despite impressive initial clinical responses, the majority of lung cancer patients treated with
paclitaxel eventually develop resistance to the drug. Pyruvate dehydrogenase kinase-2 …

Paclitaxel (or Taxol®) is a first-line chemotherapeutic drug for the treatment of non-small cell
lung cancer; however, resistance to the drug is an important factor, which influences the …

Objectives Paclitaxel (PTX) is frequently used in the clinical treatment of solid tumors. But the
PTX-resistance is a great obstacle in cancer treatment. Exploration of the mechanisms of …

Abstract Paclitaxel (PTX), a tubulin-binding agent, is widely used and has shown good
efficacy in the initial period of treatment for non-small cell lung cancer (NSCLC). However …

Paclitaxel (PTX) is one of the most efficient drugs for late-stage non-small cell lung cancer
(NSCLC) patients. However, most patients gradually develop resistance to PTX with long …